FDA Announced Clearance To Instil Bio's Early-Stage ITIL-306 Study In Cancer Settings
The U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to Instil Bio’s (NASDAQ: TIL) ITIL-306 an autologous TIL cell therapy, for the treatment for patients with with non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).
